Dr. Amogha Tadimety
Co-Founder, CEO

Amogha is a leader in translational research. Her background combines deep scientific expertise in ultrasensitive biomarker detection with industry experience in life sciences consulting and venture capital.

Dr. Alison Burklund
Co-Founder, CTO

Alison is pioneering novel approaches to rare biomarker capture and detection. She is passionate about improving global health through the development of low-cost, rapid diagnostic systems.


Dr. John Zhang

Dr. Zhang is a Nanopath cofounder and an expert in biosensing and diagnostic microsystems. He is a Professor of Engineering and Director of the Laboratory for Micro and Nanotechnology in Bioengineering at Dartmouth College.

PhD, Stanford University

Dr. Gregory J. Tsongalis

Dr. Tsongalis is the Vice Chair for Research and Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT), Director of Molecular Pathology, and Professor of Pathology and Molecular Medicine, Geisel School of Medicine, Dartmouth. 

PhD, University of Medicine and Dentistry of NJ

Sherri Oberg

Sherri is an entrepreneurial CEO with more than 20 years experience leading private, public, and NASDAQ listed companies in the biotechnology sector. She is currently Co-Founder and CEO at Particles for Humanity, PBC.

MBA, Dartmouth College

Joseph M. Vanek

 Mr. Vanek has 30 years experience in corporate strategy, intellectual property, and commercial litigation.

JD, Boston College Law School

JW Profile.JPG
Joe Wilson

 Mr. Wilson is currently a Managing Partner at Undeterred Capital.

BA, Duke University

MIT MBA drop-out

Dr. Christiaan Rees

Dr. Rees is currently a Resident Physician at Brigham and Women's Hospital 

MD, PhD, Dartmouth College